During the December 2019 SUO meeting, Urology Times interviewed UCSF Urology 
Resident Claire M. de la Calle, MD before her podium presentation. Thus far her research suggests that combining biomarkers 4Kscore or ExoDx with multiparametric MRI of the prostate leads to the smallest number of missed clinically significant prostate cancers, however the biomarkers alone still miss few clinically significant prostate cancers while avoiding more unnecessary biopsies.
"As of right now" says de la Calle, "the NCCN guidelines only mention that biomarker testing and multiparametric MRI can be considered if the patient and/or provider would like to have further information on the true risk of finding high-grade disease on biopsy. Hopefully, our current and future studies will help make the guidelines a little clearer for providers."
Click here for interview.